Persistent inflammation and immune activation have been associated with non-AIDS comorbidity and mortality in human immunodeficiency virus (HIV) infection. We aimed to investigate the potential association between soluble urokinase plasminogen activator receptor (suPAR) and incident non-AIDS comorbidity and all-cause mortality in a well-treated HIVinfected population. suPAR was measured by enzyme-linked immunosorbent assay, and events of comorbidity and mortality were ascertained by registry linkage. The study showed an independent association between a high suPAR level at baseline and increased hazard rates for both non-AIDS comorbidities (cardiovascular disease, chronic kidney disease, chronic lung disease, liver disease, and cancer) and all-cause mortality.
Introduction of antiretroviral therapy (ART) for treatment of human immunodeficiency virus (HIV) infection has led to a significant decline in AIDS-related deaths and focus has shifted to prevention and treatment of non-AIDS comorbidities. Residual immune activation and chronic inflammation is considered to be the main driver of a spectrum of comorbid events [1] .
The urokinase plasminogen activator receptor (uPAR) is a membrane-bound receptor expressed on numerous cell types. Binding of a ligand triggers an inflammatory and immune response with proteolysis, immune cell migration, and adhesion [2] . The biological function of the ligand-free uPAR is not yet well understood. Previous studies have shown that the soluble form of uPAR (suPAR) may be used as a predictive and prognostic marker of a spectrum of diseases. However, suPAR is not limited to a role as a biomarker but also appears to be a causative agent of kidney diseases and may raise new questions of a dual function in other comorbidities [3] .
In HIV infection, uPAR expression is upregulated on monocytes and T lymphocytes with highest levels in untreated HIV type 1 (HIV-1)-infected individuals [4, 5] . High levels of suPAR have both been associated with more advanced stages of HIV-1 infection and with an increased risk of mortality, and it has even been found to be a stronger predictor of mortality than CD4 T-cell count and HIV RNA [6, 7] .
The aim of this study was to examine if plasma levels of suPAR could be a predictor of all-cause mortality and incident non-AIDS comorbidity in a well-treated HIV-1-infected population.
METHOD
The study was designed as a prospective cohort study. HIVinfected adults ≥18 years of age were enrolled consecutively in the outpatient clinic of the Department of Infectious Diseases, Hvidovre Hospital, during 2007. Criteria for ART in 2007 were 1 or more of the following: acute HIV infection, CD4 T-cell count <300 cells/µL, plasma HIV RNA >100 000 copies/mL, pregnancy, or HIV-related disease.
suPAR Measurements
Blood samples were drawn at baseline and plasma was stored at -20°C until analysis. suPAR was measured in duplicate by suPARnostic enzyme-linked immunosorbent assay (ViroGates, Birkerød, Denmark). The minimum detection limit was 0.6 ng/ mL. Sample measurements were repeated if the coefficient of variation was >10%. Normal range for healthy blood donors is 2-3 ng/mL.
Ethics
The study was approved by the local ethics committee for the Capital Region of Denmark (record number H-4-2012-008) and the Danish Data Protection Agency (record numbers 2007-58-0015 and 2014-41-3492). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. the ongoing population-based prospective nationwide Danish HIV Cohort Study [8] . Anti-hepatitis C virus (HCV) antibodies and HCV RNA were determined as previously described [9] .
Data on vital status were retrieved from the Danish Civil Registration System [10] . Events of non-AIDS comorbidity were retrieved from the Danish National Patient Register based on the International Classification of Diseases, eighth and tenth revisions (ICD-8 and ICD-10) from 1977 [11] . Estimated Charlson comorbidity index score was calculated for all cases based on ICD-8 and ICD-10 codes up to inclusion.
Non-AIDS comorbidities were defined as cardiovascular disease (CVD; I20-I25, I60-I69), chronic lung disease (CLD; J40-J47, J60-J70, J82-J84), chronic kidney disease (CKD; I12.0, I13.1, N18-N19, Z49, Z94.0, Z99.2), liver disease (K70-K76), cancer (C00-C97), and diabetes mellitus (E10-E14) (see specifications in Supplementary Appendix 1).
Statistical Analysis
Multivariate Cox regression analyses with 95% confidence intervals (CIs) were used to calculate adjusted hazard ratios (aHRs) of death and incident non-AIDS comorbidity during follow-up. Variables in the model included age, sex, race, HIV transmission category, plasma HIV RNA, CD4 T-cell count, smoking status, and plasma levels of suPAR. The analyses for CKD were further adjusted by estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Each comorbidity regression analysis was performed with exclusion of individuals who had a baseline diagnosis of the specific outcome. Time was calculated from study inclusion until date of incident non-AIDS comorbidity, time of death, emigration, loss to follow-up or 22 May 2015, whichever occurred first. Interaction terms were created and stratified Cox regression analyses performed to determine possible modifiers or confounders. We used IBM SPSS Statistics for Windows, version 22.0 (IBM SPSS, Armonk, New York) to perform the analysis (see detailed statistics section in Supplementary Appendix 2).
RESULTS

Baseline Characteristics
A total of 1142 patients of the Hvidovre Hospital Clinic Cohort had plasma suPAR measured. One hundred ninety-five patients did not receive ART and were excluded. Baseline clinical and demographic characteristics of the final study participants (n = 947), including plasma suPAR levels in different subgroups, are shown in Supplementary Table 1 . In brief, the study population had a median age of 45 years; 73% were males and 78% were white. Nearly half of the study population was men who have sex with men (46%). The median plasma suPAR level at baseline was 2.65 ng/mL (interquartile range [IQR], 2.08-3.51 ng/mL; range, 0.05-21.17 ng/mL). The median time of follow-up was 7 years. There was a weak positive correlation between baseline plasma levels of suPAR and age (r = 0.121; P < .001) and HIV RNA (r = 0.105; P = .002) and a weak negative correlation between suPAR and CD4 T-cell count (r = -0.084; P = .012) and eGFR (r = -0.107; P = .001).
Plasma Levels of suPAR and Non-AIDS Comorbidity
Two hundred twenty-two (23%) individuals had 1 or more non-AIDS comorbidities registered before baseline. These individuals had significantly higher suPAR levels compared to those without any baseline comorbidity (3.06 ng/mL [IQR, 2.42-4.33]) vs 2.53 ng/mL [IQR, 2.02-3.28], respectively; P < .001). Two hundred sixty-eight (28%) incident events of non-AIDS comorbidity were registered during follow-up. With adjusted Cox regression analyses, significant associations were found between baseline plasma suPAR and incident diagnosis of CVD, CLD, CKD, liver disease, and cancer ( interactions between plasma suPAR, CVD, and route of HIV transmission (P = .015) as well as smoking (P = .005). When stratified by route of HIV transmission, a significant impact of plasma suPAR on CVD was found in participants who did not acquire HIV through injection drug use (IDU), compared with IDU-related HIV acquisition. Correspondingly, when stratified by smoking, the impact of suPAR on CVD remained significant in never smokers but not in current and previous smokers (Supplementary Table 3 ). Furthermore, a significant interaction was found between plasma suPAR, DM, and race (P = .045). When stratified by race, the impact of plasma suPAR on diabetes mellitus became significant in white individuals but not for nonwhite individuals.
Plasma Levels of suPAR and All-Cause Mortality
One hundred twenty-one (13%) deaths occurred during follow-up. suPAR and all-cause mortality and the covariates route of HIV transmission (P = .016); race (P = .001); CD4 T-cell count (P = .002); and smoking (P = .001), respectively (Supplementary Table 2 ). Stratified analyses showed higher hazard rates for non-IDU route of HIV transmission compared with IDU; nonwhite individuals compared with white; CD4 T-cell count >350 cells/ μL compared with <350 cells/μL; and previous smoking compared to current and never smoking (Supplementary Table 3 ).
Discussion
In this prospective cohort study of 947 well-treated HIVinfected individuals, we identified an independent association between high baseline plasma levels of suPAR and a spectrum of incident non-AIDS comorbidities as well as all-cause mortality during 7 years of follow-up. A high suPAR level at baseline was significantly associated with increased hazard rates of CVD, CLD, CKD, liver disease, and cancer. The associations remained strong after adjustment for traditional HIV-related risk factors and adverse lifestyle behaviors such as smoking and IDU. An interaction was discovered between suPAR and smoking in the analyses of CVD. The baseline level of suPAR in current smokers was higher than in past and never smokers, which suggests an upregulation of suPAR by smoking [12] . However, the impact of suPAR on CVD remained significant even in never smokers. Moreover, the higher suPAR level at baseline observed in individuals who acquired HIV through IDU did not seem to have an impact on cardiovascular events. Thus, suPAR may be an inflammatory marker and predictor of incident CVD in HIV-infected individuals regardless of these adverse lifestyle behaviors. Correspondingly, no confounding by smoking was found in the analyses of CLD, suggesting that the increased inflammation measured by suPAR was not triggered by smoking per se. No interactions were found between suPAR and CKD, and the association remained strong even after adjustment for eGFR. Future studies should explore the causative role of suPAR in CKD in the HIV-infected population. The liver diseases included were heterogeneous and the limited number of events prevented further stratified analyses to explore possible associations with more specific liver-related diseases. However, our findings are supported by studies from the general population where suPAR was shown to be a prognostic marker of, for example, chronic liver disease [13] . The possible pathological role of suPAR remains to be explored. Finally, suPAR may be an early predictor and prognostic marker for cancer, as shown in multiple studies from the general population, and future studies should explore this in the HIV-infected population, in which non-AIDS malignancies are of increasing concern and were recently reported to be the primary cause of death [14] .
In addition to non-AIDS comorbidities, a strong association was found between high suPAR levels at baseline and death, which supports previous studies of HIV-infected populations from the early ART era [6, 7] . The association shown in our study remained significant after adjustment for potential HIV-related confounders or effect modifiers. Interactions were found between plasma suPAR and all-cause mortality and the covariates route of HIV transmission, race, CD4 T-cell count, and smoking, respectively. In stratified analyses, the predictive value of suPAR was strongest in individuals with no other potential drivers of chronic inflammation such as IDU and smoking. Furthermore, the highest impact of suPAR on mortality was observed in nonwhite individuals compared to white individuals. Thus, our study provides additional information on suPAR as a predictor of all-cause mortality even in settings with modern ART of HIV-1 infection.
Whether suPAR is simply a prognostic marker or directly involved in the pathogenesis of non-AIDS comorbidity and all-cause mortality in HIV infection remains unclear, as suPAR was the only inflammatory marker measured and no control group was available. Future studies should include an HIV-negative control group and should explore suPAR in relation to other inflammatory markers (eg, interleukin 6, CD14, and soluble CD163) as well as additional covariates (eg, body mass index). Furthermore, studies have shown that the effect of ART is different depending on which inflammatory marker is measured [15] , and future studies should explore if the prognostic strength of suPAR in HIV infection varies with different ART regimens. Finally, no multiple comparison adjustments were performed, and a type I error cannot be excluded. However, all comorbidities would remain significant except for CKD and liver disease if a Bonferroni correction was made.
In conclusion, increased plasma levels of suPAR at baseline were associated with higher risks of non-AIDS comorbidity and all-cause mortality in this HIV-infected population. Soluble uPAR may be used as a prognostic marker in well-treated HIVinfected individuals.
